| Literature DB >> 34372744 |
Penghua Hu1,2,3, Zhiming Mo3, Yuanhan Chen2, Yanhua Wu2, Li Song2, Li Zhang2, Zhilian Li2, Lei Fu2, Huaban Liang2, Yiming Tao2, Shuangxin Liu2, Zhiming Ye2, Xinling Liang2,3.
Abstract
BACKGROUND: The study aimed to construct a clinical model based on preoperative data for predicting acute kidney injury (AKI) following cardiac surgery in patients with normal renal function.Entities:
Keywords: Cardiac surgery; acute kidney injury; normal renal function; risk model
Mesh:
Year: 2021 PMID: 34372744 PMCID: PMC8354173 DOI: 10.1080/0886022X.2021.1960563
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 2.606
Figure 1.Participant selection flow chart. eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy.
Baseline characteristics of training and validation groups.
| Variables | Training group ( | Validation group ( |
|---|---|---|
| Age, years | 47.0 ± 14.2 | 47.0 ± 14.2 |
| Male | 7711 (49.1%) | 3239 (48.7%) |
| LVEF, % | 62.9 ± 9.4 | 62.8 ± 9.4 |
| LVEF | ||
| LVEF > 60% | 11426 (72.8%) | 4813 (72.4%) |
| 40% < LVEF ≤ 60% | 3851 (24.5%) | 1649 (24.8%) |
| LVEF ≤ 40% | 424 (2.7%) | 185 (2.8%) |
| Baseline serum creatinine, µmol/l | 75.5 ± 17.3 | 75.5 ± 17.2 |
| eGFR, ml/min/1.73m2 | 94.2 ± 19.3 | 94.1 ± 19.0 |
| Comorbidities | ||
| Hypertension | 3184 (20.3%) | 1319 (19.8%) |
| Diabetes mellitus | 791 (5.0%) | 309 (4.6%) |
| Coronary heart disease | 1504 (9.6%) | 644 (9.7%) |
| COPD | 227 (1.4%) | 83 (1.2%) |
| Infectious endocarditis | 848 (5.4%) | 376 (5.7%) |
| Cerebrovascular disease | 686 (4.4%) | 305 (4.6%) |
| Peripheral vascular disease | 65 (0.4%) | 30 (0.5%) |
| Atrial fibrillation | 4073 (25.9%) | 1749 (26.3%) |
| PCI history | 159 (1.0%) | 69 (1.0%) |
| Previous cardiac surgery | 454 (2.9%) | 188 (2.8%) |
| History of transfusion | 35 (0.2%) | 16 (0.2%) |
| Recent contrast media exposure | 3543 (22.6%) | 1529 (23.0%) |
| Preoperative drugs use | ||
| Renin-angiotensin system inhibitors | 5261 (33.5%) | 2219 (33.4%) |
| NSAID | 2202 (14.0%) | 903 (13.6%) |
| Aminoglycoside antibiotics | 911 (5.8%) | 364 (5.5%) |
| Stain | 1945 (12.4%) | 810 (12.2%) |
| Proton pump inhibitors | 6458 (41.1%) | 2745 (41.3%) |
| Erythrocyte transfusion, U | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) |
| Procedure | ||
| CABG | 729 (4.6%) | 312 (4.7%) |
| Valve | 9790 (62.4%) | 4166 (62.7%) |
| Aortic | 1111 (7.1%) | 486 (7.3%) |
| CHD | 3391 (21.6%) | 1393 (21.0%) |
| CABG + valve | 456 (2.9%) | 183 (2.8%) |
| Others | 224 (1.4%) | 107 (1.6%) |
| Laboratory Findings | ||
| Hemoglobin, g/l | 134.1 ± 19.1 | 134.2 ± 19.2 |
| Platelet (×109/l) | 205.1 ± 65.2 | 205.6 ± 65.1 |
| Blood leucocytes (×109/l) | 7.2 ± 2.6 | 7.2 ± 2.7 |
| Natremia, mmol/l | 139.0 ± 2.7 | 138.9 ± 2.7 |
| Potassium, mmol/l | 3.8 ± 0.4 | 3.8 ± 0.4 |
| Magnesemia, mmol/l | 0.9 ± 0.1 | 0.9 ± 0.1 |
| Hypomagnesemia | 3395 (21.6%) | 1399 (21.0%) |
| Alanine aminotransferase, U/l | 26.1 ± 28.9 | 27.8 ± 47.3 |
| Uric acid, μmol/l | 390.8 ± 113.4 | 390.2 ± 115.9 |
| Albumin, g/l | 37.9 ± 4.9 | 37.8 ± 4.9 |
| International Normalized Ratio | 1.2 ± 0.5 | 1.2 ± 0.4 |
| Low density lipoprotein, mmol/l | 3.0 ± 0.9 | 3.0 ± 1.0 |
| Total bilirubin, μmol/l | 19.1 ± 10.8 | 19.2 ± 10.8 |
CABG: coronary artery bypass grafting; CHD: congenital heart disease; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; NSAID: non-steroidal anti-inflammatory drugs; PCI: percutaneous coronary intervention.
Figure 2.Predictor selection by the least absolute shrinkage and selection operator (LASSO) regression method. (A) The penalty tuning parameter (λ) in the LASSO model was conducted by ten-fold cross-validation with minimum criteria. Log(λ) was drawn vs. AUC. Dotted vertical lines were plotted at ideal values utilizing minimum criteria and one standard error of minimum criteria (1-SE criteria). Log(λ) of -4.528 and λ value of 0.0108 were selected. (B) Coefficient profile plot of the 35 predictors. Dotted vertical lines were plotted at ideal values utilizing the same criteria as in (A). Nine predictors with non-zero coefficients were selected.
Multivariate logistic regression analysis of variables for predicting acute kidney injury after cardiac surgery.
| variables |
| SE |
| OR | 95%CI | |
|---|---|---|---|---|---|---|
| Age, years | 0.032 | 0.002 | <0.001 | 1.032 | 1.029 | 1.036 |
| Male | 0.452 | 0.044 | <0.001 | 1.572 | 1.443 | 1.712 |
| LVEF | <0.001 | |||||
| LVEF > 60% | 1 | |||||
| 40%< LVEF ≤ 60% | 0.928 | 0.043 | <0.001 | 2.529 | 2.324 | 2.753 |
| LVEF ≤ 40% | 1.656 | 0.109 | <0.001 | 5.236 | 4.227 | 6.486 |
| Hypertension | 0.311 | 0.05 | <0.001 | 1.364 | 1.238 | 1.504 |
| Preoperative drugs use | ||||||
| Renin-angiotensin system inhibitors | 0.379 | 0.044 | <0.001 | 1.461 | 1.341 | 1.593 |
| NSAID | 0.128 | 0.056 | 0.021 | 1.137 | 1.019 | 1.267 |
| Hemoglobin, g/l | −0.023 | 0.001 | <0.001 | 0.977 | 0.975 | 0.979 |
| Hypomagnesemia | 0.252 | 0.048 | <0.001 | 1.286 | 1.172 | 1.412 |
| Uric acid, μmol/l | 0.002 | 0.000 | <0.001 | 1.002 | 1.001 | 1.002 |
| Constant | −1.065 | 0.179 | <0.001 | |||
LVEF: left ventricular ejection fraction; NSAID: non-steroidal anti-inflammatory drugs.
Figure 3.Nomogram for risk assessment of AKI after cardiac surgery in individuals who had normal kidney function. LVEF, left ventricular ejection fraction; NSAID, non-steroidal anti-inflammatory drugs; RASIs, renin-angiotensin system inhibitors.
Figure 4.Model receiver operating characteristic and calibration curves. (A) AUC for postoperative AKI was 0.751 (95% CI, 0.743–0.760) in training group. (B) Calibration curve for new model in training group. (C) AUC for postoperative AKI was 0.740 (95% CI, 0.726–0.753) in validation group. (D) Calibration curve for new model in validation group. Calibration plots illustrate the relationship between the predicted AKI risk according to the models and actual occurrence of AKI in the validation data. Plot along the 45° line represents model calibration in which predicted probabilities are identical to actual outcomes. Dotted line has a close fit to solid line, indicating a better predictive model.
Figure 5.Decision curve analyses for prediction model. X- and Y‐axes show threshold probability and net benefit, respectively. Dashed and solid black lines represent the hypothesis that no patients and all patients had AKI, respectively. Net benefit was computed by subtracting the proportion of false positives from the proportion of true positives in all patients, weighting relative harm driven by the false positive. Threshold probability was estimated as the expected benefit of avoiding treatment equivalent to the expected treatment benefit. Net new model benefits are represented for each decision threshold. Using the new model to predict the risk of postoperative AKI generated a net benefit across most of the range of prediction thresholds.